Intercept Pharmaceuticals (NASDAQ: ICPT) claims a lead position in the race to develop a treatment for non-alcoholic steatohepatitis (NASH). So when the company announced on Friday morning that it was making a significant change to its late-stage clinical study of obeticholic acid (OCA) in treating NASH, investors were eager to find out what’s going on.
Investors apparently liked what they heard: Shares jumped more than 5% on the biotech’s update. Here’s why.
Image source: Getty Images.